In this segment, the panel reviews the current therapeutic landscape for Sjögren’s Disease (SjD), emphasizing that treatment is highly individualized and guided by symptoms and organ involvement. They explain that for many patients, management begins with symptomatic therapies to address ocular and oral dryness—such as artificial tears, punctal plugs, saliva substitutes, fluoride treatments, and lifestyle adjustments. For musculoskeletal pain and fatigue, clinicians may trial hydroxychloroquine or short courses of low-dose corticosteroids, though responses vary.

When systemic disease is present—such as inflammatory arthritis, vasculitis, lung involvement, or neuropathy—treatment often escalates to immunomodulatory agents like methotrexate, azathioprine, or mycophenolate. B-cell targeted therapy, particularly rituximab, may be used in patients with more severe or refractory disease, especially when high B-cell activation or risk markers are present. The discussion underscores that despite available options, no approved disease-modifying therapy exists for SjD, highlighting a critical need for new, targeted treatments currently being explored.